IROS

vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, March 13, 2024
CGM, Administration, G42, IROS, Type 2 diabetes, Incidence, Insulin, Patient, Level 2, G&A, Doctor of Philosophy, MD, VTV, Clinical research associate, Research and development, Therapy, JDRF, PIPE, Safety, Saṃsāra, FDA, Pharmaceutical industry

HIGH POINT, N.C., March 13, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of an oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D), today reported financial results for the fourth quarter and year ended December 31, 2023, and provided an update on recent corporate developments.

Key Points: 
  • In connection with the PIPE, vTv has reduced the size of its Board of Directors from nine to seven members.
  • HIGH POINT, N.C., March 13, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of an oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D), today reported financial results for the fourth quarter and year ended December 31, 2023, and provided an update on recent corporate developments.
  • Net Loss: Net loss attributable to vTv shareholders for the year ended December 31, 2023, was $20.3 million or $9.71 per basic share.
  • Net loss attributable to vTv shareholders for the comparable period a year ago was $19.2 million or $9.98 per basic share.

vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes

Retrieved on: 
Monday, March 4, 2024
Incidence, CGM, Doctor of Philosophy, Level 2, MD, FDA, Quality of life, IROS, Safety, Diabetes, Therapy, Type 2 diabetes, Patient, Insulin, T1D, Pharmaceutical industry

This randomized, double-blind, placebo-controlled trial is expected to enroll approximately 150 patients at up to 20 sites in the United States, with the first patient expected to be enrolled in the second quarter of 2024.

Key Points: 
  • This randomized, double-blind, placebo-controlled trial is expected to enroll approximately 150 patients at up to 20 sites in the United States, with the first patient expected to be enrolled in the second quarter of 2024.
  • The Phase 3 study will assess two doses of orally administered cadisegliatin versus placebo in patients currently being treated with multiple daily insulin injections and continuous subcutaneous insulin infusion, who use a continuous glucose monitor (CGM).
  • The primary efficacy endpoint of the study will compare the incidence of Level 2 or Level 3 hypoglycemic events between cadisegliatin-treated subjects and those in the placebo group.
  • Cadisegliatin is not yet licensed or approved anywhere globally and has not been demonstrated to be safe or effective for any use.

Aurora Releases Open-Source Autonomous Driving Dataset

Retrieved on: 
Friday, June 16, 2023
Fleet Management, Autonomous Driving, Vehicles, Automotive, Other Automotive, Automotive Manufacturing, General Automotive, Vehicle Technology, Manufacturing, HD, Data set, Metadata, IROS, University, CC, Season, AUR, International Conference on Intelligent Robots and Systems, Innovation, Research, Snow, IEEE, International Conference on Parallel and Distributed Systems, Data, Creative Commons, Engineering, Open data, ATG, Amazon S3, Robotics, Aurora Innovation, Conference, Velodyne, Rain

Aurora Innovation, Inc. (NASDAQ: AUR) today publicly released the Aurora Multi-Sensor Dataset, a large-scale multi-sensor dataset with localization ground truth, in collaboration with the University of Toronto.

Key Points: 
  • Aurora Innovation, Inc. (NASDAQ: AUR) today publicly released the Aurora Multi-Sensor Dataset, a large-scale multi-sensor dataset with localization ground truth, in collaboration with the University of Toronto.
  • The Aurora Multi-Sensor Dataset was captured between January 2017 and February 2018 in the metropolitan area of Pittsburgh, PA, by Uber Advanced Technologies Group (ATG), which was acquired by Aurora in January 2021.
  • The Aurora Multi-Sensor Dataset is hosted on Amazon Simple Storage Service (S3), made available through the Open Data Sponsorship Program, and is intended for non-commercial academic use.
  • To access the Aurora Multi-Sensor Dataset, click here .

G42 Healthcare Strengthens Clinical Genomics Offering with Saphetor’s VarSome Bioinformatics Platform, Strengthens UAE’s Position as a Global Leader in Healthcare Innovation

Retrieved on: 
Monday, October 24, 2022
Biotechnology, Technology, Other Health, Health, Biometrics, Oncology, Other Technology, Medical Devices, Apps, Applications, Software, Internet, API, Health care, Life, Population, Diagnosis, Vaccine, Lists of diseases, Genomics, Volunteering, Hospital, Research, Publication, Partnership, Cancer, Technology, DNA sequencing, Disorder, NGS, Health, AI, Founder, CEO, IROS, International Grape Genome Program, Omics, Next Generation, Classification, COVID-19, Solution, Medical device, Medical imaging, Pharmaceutical industry, G42

The company recently launched over 250 comprehensive clinical genetic testing panels that use state-of-the-art sequencing technologies, with the shortest turnaround time.

Key Points: 
  • The company recently launched over 250 comprehensive clinical genetic testing panels that use state-of-the-art sequencing technologies, with the shortest turnaround time.
  • This collaboration also enables clinical genomics, at scale, as a service, using G42 Healthcares 3 genomic sequencing platforms offering both long and short read capabilities.
  • The collaboration will fortify G42 Healthcares clinical genomics solutions by leveraging the VarSome suite of bioinformatics tools to deliver valuable data insights and improved outcomes.
  • VarSome Premium and VarSome Clinical are professional editions of VarSome with powerful functionality and further sophisticated data-mining and analysis tools.

ProPhase Labs Announces Collaboration with G42 Healthcare

Retrieved on: 
Wednesday, October 19, 2022
Dietary supplement, CLIA, NASDAQ, PCR, AI, University, International Grape Genome Program, Memorandum of understanding, Nebula Genomics, OTC, Environment, DNA, RT-PCR, Chromosome, LB-2, Gene, Solution, Population, Severe acute respiratory syndrome coronavirus 2, Artificial intelligence, Private Securities Litigation Reform Act, Company, Marketing, Prophase, PIM, GLOBE, G42, Risk, Genetics, LB-1, Health care, COVID-19 testing, Laboratory, Vaccine, Organization, Volunteering, Research, Cloud computing, Ecosystem, IROS, FDM, SEC, MOU, Genomics, Hospital, Harvard Medical School, Partnership, Nasdaq, Institution, Acquisition, Omics, Food, COVID-19, TK, Antibiotics, Pharmaceutical industry, Fine chemical

ProPhase and G42 Healthcare have also entered into an initial agreement with the goal of significantly synergizing the companies genomic sequencing capabilities to support further development and globalization of their healthcare offerings.

Key Points: 
  • ProPhase and G42 Healthcare have also entered into an initial agreement with the goal of significantly synergizing the companies genomic sequencing capabilities to support further development and globalization of their healthcare offerings.
  • G42 Healthcare is a leading health-tech company that seeks to transform the UAEs healthcare landscape with AI and advanced medical technologies.
  • G42 Healthcare is an enabler of the worlds largest and most comprehensive population genomics initiative the Emirati Genome Program, which aims to move the traditional ecosystem from sick care to preventive healthcare for UAEs citizens, making G42 Healthcare an ideal strategic relationship for ProPhase as we look to bolster our next generation sequencing capabilities and build our new state-of-the-art genomic sequencing facility, commented Ted Karkus, ProPhase Labs Chief Executive Officer.
  • As an active advisor to both ProPhase Labs and G42, I am excited that this collaboration brings together two organizations that are leaders in next-generation sequencing.

Acceleration Robotics Announce and Open Sources ROBOTCORE®, the First Robotic Processing Unit – Specialized in ROS Computations

Retrieved on: 
Thursday, September 29, 2022
Semiconductor, Automotive, General Automotive, Technology, Software, Hardware, Field-programmable gate array, Basque Country, Time, Demography of London, Acceleration, Hardware acceleration, Robot Operating System, NVIDIA, Central processing unit, Language, Library, ROS, Robotics, RPU, Map, Silicon, API, FPGA, Robot, Roscón, Graphics processing unit, GPU, AMD, IROS, Systems architect, Computer data storage, Xilinx

Acceleration Robotics a robotics semiconductor startup based in the Basque Country, Spain has announced ROBOTCORE , a robot-specific processing unit for the robotics architect.

Key Points: 
  • Acceleration Robotics a robotics semiconductor startup based in the Basque Country, Spain has announced ROBOTCORE , a robot-specific processing unit for the robotics architect.
  • The design files of ROBOTCORE have been disclosed and open sourced at the ROS 2 Hardware Acceleration Working Group.
  • Robotic Processing Unit (RPUs) are robot brains, processing units for robots that map efficiently robot behaviors (programmed as ROS computational graphs) to underlying compute resources.
  • The robotic processing unit is powered by the technologies of AMD and NVIDIA, packing best-of-class accelerators from top silicon vendors.

EZ-Robot Provides Robotics Education to Future-Proof Youth

Retrieved on: 
Thursday, September 8, 2022
Machine learning, Workforce, Mathematics, Technology, Education, A.I, Artificial intelligence, RRSP, Engineering, School, Robotics, USD, Literacy, TFSA, STEAM, World Economic Forum, Learning, Science, Student, Thought, GLOBE, Workplace, History, IROS, Automation, Growth, Management, Tutoring, Medicine, Toy, STEM

CALGARY, Alberta, Sept. 08, 2022 (GLOBE NEWSWIRE) -- With the rapid implementation of machine learning, A.I. (artificial intelligence), and automation, it’s more important than ever for students to learn about robotics and technology.

Key Points: 
  • (artificial intelligence), and automation, its more important than ever for students to learn about robotics and technology.
  • Robotics education gives students the skills theyll need in an increasingly technological world.
  • Over the past decade, he has taught and demonstrated robotics to more than 20,000 students and helped more than 22,000 educators understand how robotics and A.I.
  • Schools that implement his strategies see enrollment in robotics and computer science programs increase up to tenfold.

Towards Robot Accelerators, Democratizing Hardware Acceleration in Robotics

Retrieved on: 
Monday, July 25, 2022
Software, Technology, Hardware, Semiconductor, Demography of London, CPU, Silicon, IROS, Research, AMD, Solution, International Conference on Intelligent Robots and Systems, Behavior tree (artificial intelligence, robotics and control), Central processing unit, Graphics processing unit, Conference, Robotics, Robot Operating System, Open architecture, Technology, Basque Country, Systems architect, International Conference on Human-Robot Interaction, Robot, Acceleration, Hardware acceleration, ROS, Field-programmable gate array, Harvard University, Computer data storage, Node, Xilinx

Acceleration Robotics a robotics semiconductor startup based in the Basque Country, Spain together with Prof. Vijay Janapa Reddi from Harvard University and researchers at the Harvard Edge Computing Lab will present next October in Japan their latest work on democratizing the use of hardware acceleration in robotics in a scalable, vendor- and technology-agnostic manner.

Key Points: 
  • Acceleration Robotics a robotics semiconductor startup based in the Basque Country, Spain together with Prof. Vijay Janapa Reddi from Harvard University and researchers at the Harvard Edge Computing Lab will present next October in Japan their latest work on democratizing the use of hardware acceleration in robotics in a scalable, vendor- and technology-agnostic manner.
  • Titled as RobotCore: An Open Architecture for Hardware Acceleration in ROS 2 , their paper describes and discloses a reference implementation of the architectural pillars and the programming conventions required to introduce hardware acceleration in robotics in a sustainable manner, avoiding semiconductor vendor lock-ins.
  • Shortly, hardware acceleration allows the creation of custom compute architectures (named robot accelerators or cores) that exploit compute parallelism.
  • We demonstrated in our work how hardware acceleration combining FPGAs and GPUs properly can revolutionize robotics, increasing determinism and speeding up robot response times enabling new applications with robots.

Alias Robotics discovers numerous and dangerous vulnerabilities in the Robot Operating System's (ROS) communications that can have "devastating consequences"

Retrieved on: 
Wednesday, March 30, 2022
Cloud, ROS, Organization, Robotics, Internet service provider, Robot Operating System, NASA, IROS, University, Internet, European Commission, Trend Micro, Control channel, Research, Security, Conference, Health, Communication, Robot, Data Distribution Service, Software, Royal commission, Industry, Technology, Safety, Immune system, RIS, Solution, International Conference on Applied Human Factors and Ergonomics, DDS, Security agency, Medical device, Computer data storage, Hospital

From Alias Robotics -specialized in robot cyber security- it is considered that "DDS is a middlewarestill largely insecure communications technology , used in areas where security is very important, so investment in cybersecurity is needed immediately".

Key Points: 
  • From Alias Robotics -specialized in robot cyber security- it is considered that "DDS is a middlewarestill largely insecure communications technology , used in areas where security is very important, so investment in cybersecurity is needed immediately".
  • Based on the security-immaturity of DDS, the appearance of new vulnerabilities affecting DDS in the coming months is not ruled out.
  • Aliases Robotics was founded in 2018 by Vctor Mayoral-Vilches and has become an international leader in cybersecurity solutions for robots.
  • Alias Robotics is made up of renowned robotics engineers, scientists and security researchers with more than 10 years of experience.

Alias Robotics discovers numerous and dangerous vulnerabilities in the Robot Operating System's (ROS) communications that can have "devastating consequences"

Retrieved on: 
Wednesday, March 30, 2022
Cloud, ROS, Organization, Robotics, Internet service provider, Robot Operating System, NASA, IROS, University, Internet, European Commission, Trend Micro, Control channel, Research, Security, Conference, Health, Communication, Robot, Data Distribution Service, Software, Royal commission, Industry, Technology, Safety, Immune system, RIS, Solution, International Conference on Applied Human Factors and Ergonomics, DDS, Security agency, Medical device, Computer data storage, Hospital

From Alias Robotics -specialized in robot cyber security- it is considered that "DDS is a middlewarestill largely insecure communications technology , used in areas where security is very important, so investment in cybersecurity is needed immediately".

Key Points: 
  • From Alias Robotics -specialized in robot cyber security- it is considered that "DDS is a middlewarestill largely insecure communications technology , used in areas where security is very important, so investment in cybersecurity is needed immediately".
  • Based on the security-immaturity of DDS, the appearance of new vulnerabilities affecting DDS in the coming months is not ruled out.
  • Aliases Robotics was founded in 2018 by Vctor Mayoral-Vilches and has become an international leader in cybersecurity solutions for robots.
  • Alias Robotics is made up of renowned robotics engineers, scientists and security researchers with more than 10 years of experience.